FDA peptide review lifts Hims & Hers shares
Hims & Hers rose as much as 25% after Robert F. Kennedy Jr. said the FDA plans to remove 12 peptides from Category 2, potentially shifting more peptide demand into regulated channels.
From the sources (6 posts)
@wallstengineRFK JR: FDA TO REMOVE MANY PEPTIDES FROM CATEGORY TWO $HIMS
@businessHims & Hers Health Inc. surged as much as 12% after Health Secretary Robert F. Kennedy Jr. said US drug regulators will loosen restrictions around a dozen popular peptide injections.
@stocksavvyshayRFK Jr. said the FDA plans to remove 12 peptides from Category 2. Moving peptides out of the gray market and into regulated channels could create a more credible and scalable opportunity for $HIMS.
@polymarketmoneyRFK Jr. said the FDA plans to remove 12 peptides from Category 2, a move $HIMS praised as a step toward clearer regulation and more legitimate medical oversight. The update could help shift peptide therapies further out of the gray market
@wallstengine$HIMS shares are up more than 20% after RFK Jr. said the FDA will reevaluate several wellness peptides now under restriction. The move is only procedural for now, but it could open future peptide revenue streams and help redeploy GLP-1 capa
@stocksavvyshay$HIMS jumped almost 25% after RFK Jr. said the FDA will reevaluate several restricted wellness peptides. That likely helped fuel the move since Hims already owns a dedicated peptide manufacturing facility in California and looks well posit